Acute myeloid leukemia is divided into 7 subgroups (M0-M7). The group division is based on the morphological examination after the FAB-classification of blood and bone marrow smears and can be supported by immunophenotyping, cytogenetic, and molecular genetic testing, as well as combinations of these techniques. This is done in the WHO staging which is increasingly applied also in Norway.
It is important to obtain a diagnosis and determine which subgroup the patient belongs to. The more rare subgroup, M3 (acute hypergranular promyelocyte leukemia), is especially important to identify as it is often accompanied by non-compensated disseminated intravascular coagulation (DIC). This type of leukemia requires special treatment which must be started immediately when there is a well-founded suspicion of this diagnosis. With correct treatment the prognosis is far better than for the other subgroups.
The type of chromosome changes in leukemia cells at the time of diagnosis may be of importance for treating patients, especially those under 60 years. Patients are divided according to low and high risk criteria.
- Suspicion of acute myeloid leukemia
- Confirm the diagnosis
- Identify risk group for disease progression
- Cure the disease
Norsk selskap for hematologi. Akutt myelogen leukemi, handlingsprogram [Online]. Februar 2007 [hentet 15. april 2007]; tilgjengelig fra: URL: http://www.legeforeningen.no/asset/15380/1/15380_1.doc